KB-1526

Eflimrufusp alfa

×
Please enable JavaScript in your browser to complete this form.
45856
Home » Antibodies » Eflimrufusp alfa

Background of Eflimrufusp alfa

Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are critical mediators in angiogenesis-related diseases. RC28-E, a soluble fusion protein, is composed of the extracellular domain 2 (ECD 2) of human VEGF receptor 1 (VEGFR1), ECD 3 of VEGFR2, ECDs 2 and 3 of FGFR1, and the Fc region of human immunoglobulin G1. Eflimrufusp alfa functions by reducing the formation of new blood vessels through the inhibition of VEGF and basic fibroblast growth factor (bFGF) activity. This mechanism is effective in controlling pathological angiogenesis associated with various ocular diseases.

Specifications

Catalog NumberKB-1526
Antibody NameEflimrufusp alfa
IsotypeHuman IgG1
FC MuationsWild Type
TargetFGF2
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Ruch C, Skiniotis G, Steinmetz M, et al. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol. 2007;14:249-250.
  2. Flippot R, Kone M, Magné N, et al. FGF/FGFR signalling: implication in oncogenesis and perspectives. Bull Cancer. 2015;102:516-526.
Please enable JavaScript in your browser to complete this form.